Balancing and communicating the risks and benefits of biologics in pediatric inflammatory bowel disease

Inflammatory Bowel Diseases

Volumn 19, Issue 13, 2013, Pages 2927-2936

  Dulai, Parambir S ^a   Siegel, Corey A ^a   Dubinsky, Marla C ^b  

^a DARTMOUTH HITCHCOCK MEDICAL CENTER   (United States)

^b CEDARS SINAI MEDICAL CENTER   (United States)

Author keywords

Anti TNF; Crohn's disease; Option Grid; Pediatric inflammatory bowel disease; Risk; Shared decision making; Ulcerative colitis

Indexed keywords

INFLIXIMAB;

ADVERSE DRUG REACTION; ANEMIA; ARTHRALGIA; AUTOIMMUNITY; BASAL CELL CARCINOMA; CARDIOMYOPATHY; CHILD DEVELOPMENT; CHILD GROWTH; CROHN DISEASE; DRUG EFFICACY; DRUG SAFETY; HEALTH CARE; HEALTH HAZARD; HEALTH LITERACY; HEART FAILURE; HUMAN; HYPERTRANSAMINASEMIA; IMMUNOGENICITY; INFECTION RATE; INFLAMMATORY BOWEL DISEASE; MEDICAL DECISION MAKING; MONOTHERAPY; NEUTROPENIA; NONHODGKIN LYMPHOMA; PANCREATITIS; PARENT; PHYSICIAN; PRIORITY JOURNAL; PSORIASIS; REVIEW; SUICIDE ATTEMPT; ULCERATIVE COLITIS;

ANTIBODIES, MONOCLONAL; BIOLOGICAL FACTORS; CHILD; COLITIS, ULCERATIVE; CROHN DISEASE; DECISION MAKING; HUMANS; RISK ASSESSMENT; RISK FACTORS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84893750589     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1097/MIB.0b013e31829aad16     Document Type: Review

References (104)

1. Schildkraut V, Alex G, Cameron DJ, et al. Sixty-year study of incidence of childhood ulcerative colitis finds eleven-fold increase beginning in 1990s. Inflamm Bowel Dis. 2013;19:1-6.
2. Martin-de-Carpi J, Rodriguez A, Ramos E, et al SPIRIT-IBD Working Group of SEGHNP (Sociedad Espanola de Gastroenterologia, Hepatologia y Nutricion Pediatrica). Increasing incidence of pediatric inflammatory bowel disease in Spain (1996-2009): the SPIRIT registry. Inflamm Bowel Dis. 2013;19:73-80.
3. Benchimol EI, Fortinsky KJ, Gozdyra P, et al. Epidemiology of pediatric inflammatory bowel disease: a systematic review of international trends. Inflamm Bowel Dis. 2011;17:423-439.
4. Karwowski CA, Keljo D, Szigethy E. Strategies to improve quality of life in adolescents with inflammatory bowel disease. Inflamm Bowel Dis. 2009;15:1755-1764.
5. Levine A, Griffiths A, Markowitz J, et al. Pediatric modification of the Montreal classification for inflammatory bowel disease: the Paris classification. Inflamm Bowel Dis. 2011;17:1314-1321.
6. Abraham C, Cho JH. Inflammatory bowel disease. N Engl J Med. 2009; 361:2066-2078.
7. Barnes MJ, Powrie F. Regulatory T cells reinforce intestinal homeostasis. Immunity. 2009;31:401-411.
8. Glocker EO, Kotlarz D, Boztug K, et al. Inflammatory bowel disease and mutations affecting the interleukin-10 receptor. N Engl J Med. 2009;361: 2033-2045.
9. Neurath MF, Travis SP. Mucosal healing in inflammatory bowel diseases: a systematic review. Gut. 2012;61:1619-1635.
10. Siegel CA, Levy LC, Mackenzie TA, et al. Patient perceptions of the risks and benefits of infliximab for the treatment of inflammatory bowel disease. Inflamm Bowel Dis. 2008;14:1-6.
11. Siegel CA. Shared decision making in inflammatory bowel disease: helping patients understand the tradeoffs between treatment options. Gut. 2012;61:459-465.
12. Hyams JS, Markowitz J, Wyllie R. Use of infliximab in the treatment of Crohn's disease in children and adolescents. J Pediatr. 2000;137:192-196.
13. Kugathasan S, Werlin SL, Martinez A, et al. Prolonged duration of response to infliximab in early but not late pediatric Crohn's disease. Am J Gastroenterol. 2000;95:3189-3194.
14. Baldassano R, Braegger CP, Escher JC, et al. Infliximab (REMICADE) therapy in the treatment of pediatric Crohn's disease. Am J Gastroenterol. 2003;98:833-838.
15. Cezard JP, Nouaili N, Talbotec C, et al. A prospective study of the efficacy and tolerance of a chimeric antibody to tumor necrosis factors (remicade) in severe pediatric Crohn disease. J Pediatr Gastroenterol Nutr. 2003;36:632-636.
16. Borrelli O, Bascietto C, Viola F, et al. Infliximab heals intestinal inflammatory lesions and restores growth in children with Crohn's disease. Dig Liver Dis. 2004;36:342-347.
17. Crandall W, Hyams J, Kugathasan S, et al. Infliximab therapy in children with concurrent perianal Crohn disease: observations from REACH. J Pediatr Gastroenterol Nutr. 2009;49:183-190.
18. Hyams J, Crandall W, Kugathasan S, et al. Induction and maintenance infliximab therapy for the treatment of moderate-to-severe Crohn's disease in children. Gastroenterology. 2007;132:863-873; quiz 1165-1166.
19. Ruemmele FM, Lachaux A, Cezard JP, et al. Efficacy of infliximab in pediatric Crohn's disease: a randomized multicenter open-label trial comparing scheduled to on demand maintenance therapy. Inflamm Bowel Dis. 2009;15:388-394.
20. Crombe V, Salleron J, Savoye G, et al. Long-term outcome of treatment with infliximab in pediatric-onset Crohn's disease: a population-based study. Inflamm Bowel Dis. 2011;17:2144-2152.
21. Hyams J,Walters TD, Crandall W, et al. Safety and efficacy of maintenance infliximab therapy for moderate-to-severe Crohn's disease in children: REACH open-label extension. Curr Med Res Opin. 2011;27:651-662.
22. Colombel JF, Sandborn WJ, Rutgeerts P, et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. Gastroenterology. 2007;132:52-65.
23. Sandborn WJ, Rutgeerts P, Enns R, et al. Adalimumab induction therapy for Crohn disease previously treated with infliximab: a randomized trial. Ann Intern Med. 2007;146:829-838.
24. Rosh JR, Lerer T, Markowitz J, et al. Retrospective evaluation of the safety and effect of adalimumab therapy (RESEAT) in pediatric Crohn's disease. Am J Gastroenterol. 2009;104:3042-3049.
25. Russell RK, Wilson ML, Loganathan S, et al. A British Society of Paediatric Gastroenterology, Hepatology and Nutrition survey of the effectiveness and safety of adalimumab in children with inflammatory bowel disease. Aliment Pharmacol Ther. 2011;33:946-953.
26. Viola F, Civitelli F, Di Nardo G, et al. Efficacy of adalimumab in moderate-to-severe pediatric Crohn's disease. Am J Gastroenterol. 2009;104:2566-2571.
27. Wyneski MJ, Green A, Kay M, et al. Safety and efficacy of adalimumab in pediatric patients with Crohn disease. J Pediatr Gastroenterol Nutr. 2008;47:19-25.
28. Rosenbach Y, Hartman C, Shapiro R, et al. Adalimumab treatment in children with refractory Crohn's disease. Dig Dis Sci. 2010;55:747-753.
29. Hyams JS, Griffiths A, Markowitz J, et al. Safety and efficacy of adalimumab for moderate to severe Crohn's disease in children. Gastroenterology. 2012;143:365-374.e2.
30. Turner D, Mack D, Leleiko N, et al. Severe pediatric ulcerative colitis: a prospective multicenter study of outcomes and predictors of response. Gastroenterology. 2010;138:2282-2291.
31. Hyams JS, Lerer T, Griffiths A, et al. Outcome following infliximab therapy in children with ulcerative colitis. Am J Gastroenterol. 2010; 105:1430-1436.
32. Heuschkel R, Salvestrini C, Beattie RM, et al. Guidelines for the management of growth failure in childhood inflammatory bowel disease. Inflamm Bowel Dis. 2008;14:839-849.
33. Kanof ME, Lake AM, Bayless TM. Decreased height velocity in children and adolescents before the diagnosis of Crohn's disease. Gastroenterology. 1988;95:1523-1527.
34. Hildebrand H, Karlberg J, Kristiansson B. Longitudinal growth in children and adolescents with inflammatory bowel disease. J Pediatr Gastroenterol Nutr. 1994;18:165-173.
35. Walters TD, Gilman AR, Griffiths AM. Linear growth improves during infliximab therapy in children with chronically active severe Crohn's disease. Inflamm Bowel Dis. 2007;13:424-430.
36. Malik S, Wong SC, Bishop J, et al. Improvement in growth of children with Crohn disease following anti-TNF-alpha therapy can be independent of pubertal progress and glucocorticoid reduction. J Pediatr Gastroenterol Nutr. 2011;52:31-37.
37. Thayu M, Leonard MB, Hyams JS, et al. Improvement in biomarkers of bone formation during infliximab therapy in pediatric Crohn's disease: results of the REACH study. Clin Gastroenterol Hepatol. 2008;6: 1378-1384.
38. Turner D, Travis SP, Griffiths AM, et al. Consensus for managing acute severe ulcerative colitis in children: a systematic review and joint statement from ECCO, ESPGHAN, and the porto IBD working group of ESPGHAN. Am J Gastroenterol. 2011;106:574-588.
39. Turner D, Levine A, Escher JC, et al. Management of pediatric ulcerative colitis: joint ECCO and ESPGHAN evidence-based consensus guidelines. J Pediatr Gastroenterol Nutr. 2012;55:340-361.
40. de Bie CI, Escher JC, de Ridder L. Antitumor necrosis factor treatment for pediatric inflammatory bowel disease. Inflamm Bowel Dis. 2012;18: 985-1002.
41. Veres G, Baldassano RN, Mamula P. Infliximab therapy in children and adolescents with inflammatory bowel disease. Drugs. 2007;67:1703-1723.
42. Candon S, Mosca A, Ruemmele F, et al. Clinical and biological consequences of immunization to infliximab in pediatric Crohn's disease. Clin Immunol. 2006;118:11-19.
43. Miele E, Markowitz JE, Mamula P, et al. Human antichimeric antibody in children and young adults with inflammatory bowel disease receiving infliximab. J Pediatr Gastroenterol Nutr. 2004;38:502-508.
44. Baert F, Noman M, Vermeire S, et al. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. N Engl J Med. 2003;348:601-608.
45. Kugathasan S, Levy MB, Saeian K, et al. Infliximab retreatment in adults and children with Crohn's disease: risk factors for the development of delayed severe systemic reaction. Am J Gastroenterol. 2002;97:1408-1414.
46. Cheifetz A, Smedley M, Martin S, et al. The incidence and management of infusion reactions to infliximab: a large center experience. Am J Gastroenterol. 2003;98:1315-1324.
47. Wanty C, Stephenne X, Sokal E, et al. Long-term outcome of infliximab therapy in pediatric Crohn disease. Arch Pediatr. 2011;18:863-869.
48. de Ridder L, Rings EH, Damen GM, et al. Infliximab dependency in pediatric Crohn's disease: long-term follow-up of an unselected cohort. Inflamm Bowel Dis. 2008;14:353-358.
49. Duricova D, Pedersen N, Lenicek M, et al. Infliximab dependency in children with Crohn's disease. Aliment Pharmacol Ther. 2009;29:792-799.
50. Wewer V, Riis L, Vind I, et al. Infliximab dependency in a national cohort of children with Crohn's disease. J Pediatr Gastroenterol Nutr. 2006;42:40-45.
51. de Bie CI, Hummel TZ, Kindermann A, et al. The duration of effect of infliximab maintenance treatment in paediatric Crohn's disease is limited. Aliment Pharmacol Ther. 2011;33:243-250.
52. Mamula P, Markowitz JE, Brown KA, et al. Infliximab as a novel therapy for pediatric ulcerative colitis. J Pediatr Gastroenterol Nutr. 2002;34:307-311.
53. Mamula P, Markowitz JE, Cohen LJ, et al. Infliximab in pediatric ulcerative colitis: two-year follow-up. J Pediatr Gastroenterol Nutr. 2004;38:298-301.
54. Russell GH, Katz AJ. Infliximab is effective in acute but not chronic childhood ulcerative colitis. J Pediatr Gastroenterol Nutr. 2004;39:166-170.
55. Eidelwein AP, Cuffari C, Abadom V, et al. Infliximab efficacy in pediatric ulcerative colitis. Inflamm Bowel Dis. 2005;11:213-218.
56. Fanjiang G, Russell GH, Katz AJ. Short-and long-term response to and weaning from infliximab therapy in pediatric ulcerative colitis. J Pediatr Gastroenterol Nutr. 2007;44:312-317.
57. Cucchiara S, Romeo E, Viola F, et al. Infliximab for pediatric ulcerative colitis: a retrospective Italian multicenter study. Dig Liver Dis. 2008;40 (Suppl 2):S260-S264.
58. McGinnis JK, Murray KF. Infliximab for ulcerative colitis in children and adolescents. J Clin Gastroenterol. 2008;42:875-879.
59. Turner D, Griffiths AM. Acute severe ulcerative colitis in children: a systematic review. Inflamm Bowel Dis. 2011;17:440-449.
60. Lionetti P, Bronzini F, Salvestrini C, et al. Response to infliximab is related to disease duration in paediatric Crohn's disease. Aliment Pharmacol Ther. 2003;18:425-431.
61. Lamireau T, Cezard JP, Dabadie A, et al. Efficacy and tolerance of infliximab in children and adolescents with Crohn's disease. Inflamm Bowel Dis. 2004;10:745-750.
62. Afzal NA, Ozzard A, Keady S, et al. Infliximab delays but does not avoid the need for surgery in treatment-resistant pediatric Crohn' disease. Dig Dis Sci. 2007;52:3329-3333.
63. Wynands J, Belbouab R, Candon S, et al. 12-month follow-up after successful infliximab therapy in pediatric Crohn disease. J Pediatr Gastroenterol Nutr. 2008;46:293-298.
64. Lee JS, Lee JH, Lee JH, et al. Efficacy of early treatment with infliximab in pediatric Crohn's disease. World J Gastroenterol. 2010;16:1776-1781.
65. Sinitsky DM, Lemberg DA, Leach ST, et al. Infliximab improves inflammation and anthropometric measures in pediatric Crohn's disease. J Gastroenterol Hepatol. 2010;25:810-816.
66. Kim MJ, Lee JS, Lee JH, et al. Infliximab therapy in children with Crohn's disease: a one-year evaluation of efficacy comparing 'top-down' and 'step-up' strategies. Acta Paediatr. 2011;100:451-455.
67. Kierkus J, Dadalski M, Szymanska E, et al. The impact of infliximab induction therapy on mucosal healing and clinical remission in polish pediatric patients with moderate-to-severe Crohn's disease. Eur J Gastroenterol Hepatol. 2012;24:495-500.
68. Stephens MC, Shepanski MA, Mamula P, et al. Safety and steroid-sparing experience using infliximab for Crohn's disease at a pediatric inflammatory bowel disease center. Am J Gastroenterol. 2003;98:104-111.
69. Hyams JS, Lerer T, Griffiths A, et al. Long-term outcome of maintenance infliximab therapy in children with Crohn's disease. Inflamm Bowel Dis. 2009;15:816-822.
70. de Ridder L, Escher JC, Bouquet J, et al. Infliximab therapy in 30 patients with refractory pediatric Crohn disease with and without fistulas in the Netherlands. J Pediatr Gastroenterol Nutr. 2004;39:46-52.
71. Teitelbaum JE, Saeed S, Triantafyllopoulou M, et al. Infliximab in pediatric Crohn disease patients with enterovesicular fistulas. J Pediatr Gastroenterol Nutr. 2007;44:279-282.
72. Afzal NA, Shenoy MU, Haque S, et al. Recognition and treatment of genitourinary complications in paediatric Crohn's disease using infliximab. Acta Paediatr. 2010;99:1042-1046.
73. Keljo DJ, Markowitz J, Langton C, et al. Course and treatment of perianal disease in children newly diagnosed with Crohn's disease. Inflamm Bowel Dis. 2009;15:383-387.
74. Crandall WV, Mackner LM. Infusion reactions to infliximab in children and adolescents: frequency, outcome and a predictive model. Aliment Pharmacol Ther. 2003;17:75-84.
75. Friesen CA, Calabro C, Christenson K, et al. Safety of infliximab treatment in pediatric patients with inflammatory bowel disease. J Pediatr Gastroenterol Nutr. 2004;39:265-269.
76. Jacobstein DA, Markowitz JE, Kirschner BS, et al. Premedication and infusion reactions with infliximab: results from a pediatric inflammatory bowel disease consortium. Inflamm Bowel Dis. 2005;11:442-446.
77. Lahdenne P, Wikstrom AM, Aalto K, et al. Prevention of acute adverse events related to infliximab infusions in pediatric patients. Arthritis Care Res. 2010;62:785-790.
78. West RL, Zelinkova Z, Wolbink GJ, et al. Immunogenicity negatively influences the outcome of adalimumab treatment in Crohn's disease. Aliment Pharmacol Ther. 2008;28:1122-1126.
79. Karmiris K, Paintaud G, Noman M, et al. Influence of trough serum levels and immunogenicity on long-term outcome of adalimumab therapy in Crohn's disease. Gastroenterology. 2009;137:1628-1640.
80. Dulai PS, Dubinsky MC, Siegel CA. Systematic review of serious infection and lymphoma risk with anti-TNF therapy for pediatric IBD. Gastroenterology. 2013;144:S112.
81. Siegel CA, Marden SM, Persing SM, et al. Risk of lymphoma associated with combination anti-tumor necrosis factor and immunomodulator therapy for the treatment of Crohn's disease: a meta-analysis. Clin Gastroenterol Hepatol. 2009;7:874-881.
82. Ashworth LA, Billett A, Mitchell P, et al. Lymphoma risk in children and young adults with inflammatory bowel disease: analysis of a large single-center cohort. Inflamm Bowel Dis. 2012;18:838-843.
83. Lichtenstein GR, Rutgeerts P, Sandborn WJ, et al. A pooled analysis of infections, malignancy, and mortality in infliximab-and immunomodulatortreated adult patients with inflammatory bowel disease. Am J Gastroenterol. 2012;107:1051-1063.
84. Kotlyar DS, Osterman MT, Diamond RH, et al. A systematic review of factors that contribute to hepatosplenic T-cell lymphoma in patients with inflammatory bowel disease. Clin Gastroenterol Hepatol. 2011;9:36-41.e1.
85. Kotlyar DS, Blonski W, Diamond RH, et al. Hepatosplenic T-cell lymphoma in inflammatory bowel disease: a possible thiopurine-induced chromosomal abnormality. Am J Gastroenterol. 2010;105:2299-2301.
86. Chung ES, Packer M, Lo KH, et al Anti-TNF Therapy Against Congestive Heart Failure Investigators. Randomized, double-blind, placebocontrolled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-alpha, in patients with moderate-to-severe heart failure: results of the anti-TNF therapy against congestive heart failure (ATTACH) trial. Circulation. 2003;107:3133-3140.
87. Barbato M, Curione M, Viola F, et al. Cardiac involvement in children with IBD during infliximab therapy. Inflamm Bowel Dis. 2006;12:828-829.
88. D'Haens G, Baert F, van Assche G, et al. Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial. Lancet. 2008;371:660-667.
89. Colombel JF, Sandborn WJ, Reinisch W, et al. Infliximab, azathioprine, or combination therapy for Crohn's disease. N Engl J Med. 2010;362: 1383-1395.
90. Johnson FR, Ozdemir S, Mansfield C, et al. Are adult patients more tolerant of treatment risks than parents of juvenile patients? Risk Anal. 2009;29:121-136.
91. Siegel CA. Making therapeutic decisions in inflammatory bowel disease: the role of patients. Curr Opin Gastroenterol. 2009;25:334-338.
92. DeWalt DA, Hink A. Health literacy and child health outcomes: a systematic review of the literature. Pediatrics. 2009;124(Suppl 3): S265-S274.
93. Yin HS, Johnson M, Mendelsohn AL, et al. The health literacy of parents in the United States: a nationally representative study. Pediatrics. 2009; 124(Suppl 3):S289-S298.
94. Yin HS, Dreyer BP, Vivar KL, et al. Perceived barriers to care and attitudes towards shared decision-making among low socioeconomic status parents: role of health literacy. Acad Pediatr. 2012;12:117-124.
95. Shone LP, Conn KM, Sanders L, et al. The role of parent health literacy among urban children with persistent asthma. Patient Educ Couns. 2009; 75:368-375.
96. Runeson I, Martenson E, Enskar K. Children's knowledge and degree of participation in decision making when undergoing a clinical diagnostic procedure. Pediatr Nurs. 2007;33:505-511.
97. Greenley RN, Kunz JH, Biank V, et al. Identifying youth nonadherence in clinical settings: data-based recommendations for children and adolescents with inflammatory bowel disease. Inflamm Bowel Dis. 2012; 18:1254-1259.
98. Huang JS, Tobin A, Tompane T. Clinicians poorly assess health literacyrelated readiness for transition to adult care in adolescents with inflammatory bowel disease. Clin Gastroenterol Hepatol. 2012;10:626-632.
99. Benchimol EI, Walters TD, Kaufman M, et al. Assessment of knowledge in adolescents with inflammatory bowel disease using a novel transition tool. Inflamm Bowel Dis. 2011;17:1131-1137.
100. Knopf JM, Hornung RW, Slap GB, et al. Views of treatment decision making from adolescents with chronic illnesses and their parents: a pilot study. Health Expect. 2008;11:343-354.
101. Britto MT, DeVellis RF, Hornung RW, et al. Health care preferences and priorities of adolescents with chronic illnesses. Pediatrics. 2004;114: 1272-1280.
102. Weithorn LA, Campbell SB. The competency of children and adolescents to make informed treatment decisions. Child Dev. 1982;53: 1589-1598.
103. Stacey D, Bennett CL, Barry MJ, et al. Decision aids for people facing health treatment or screening decisions. Cochrane Database Syst Rev. 2011;(10):CD001431.
104. Elwyn G, Lloyd A, Joseph-Williams N, et al. Option grids: shared decision making made easier. Patient Educ Couns. 2013;90:207-212.